Labcorp announces 2025 first quarter results

Updates full-year guidance results from operations for first quarter 2025 versus first quarter last year: revenue: $3.35 billion versus $3.18 billion diluted eps: $2.52 versus $2.69 adjusted eps: $3.84 versus $3.68 reaffirmed revenue and free cash flow guidance, raised midpoint of adjusted eps: revenue guidance of 6.7% to 8.0% adjusted eps range of $15.70 to $16.40; midpoint raised $0.05 free cash flow of $1.10 billion to $1.25 billion providing broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-date introduced new tests including labcorp plasma complete, a liquid biopsy test for cancer, and ptau-217/beta amyloid 42 ratio test to aid in the diagnosis of alzheimer's disease burlington, n.c. , april 29, 2025 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended march 31, 2025 and updated full-year guidance.
LH Ratings Summary
LH Quant Ranking